This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parker, J. O. Articles by Stone, J. A. Search for Related Content PubMed PubMed Citation Articles by Parker, J. O. Articles by Stone, J. A.

Circulation, Vol 68, 1074-1080, Copyright © 1983 by American Heart Association

ARTICLES

Tolerance to isosorbide dinitrate: rate of development and reversal

JO Parker, HL Fung, D Ruggirello and JA Stone

The circulatory response and plasma concentrations of isosorbide dinitrate (ISDN) were determined in 10 patients with chronic, stable angina after administration of 5 mg of sublingual ISDN during the control stage, after 48 hr of therapy with 15 mg of ISDN orally every 6 hr, and subsequently after a 48 hr period when ISDN was substituted by placebo four times daily. Initially, sublingual ISDN induced major reductions in both supine and standing systolic and diastolic blood pressure, but after 45 hr of therapy with oral ISDN, there was a significantly diminished vasodepressor response in both positions. Subsequently, when placebo was substituted for ISDN, the circulatory response initially seen was restored within 21 hr. Plasma ISDN concentrations after the test sublingual dose were slightly higher after 48 hr of oral ISDN dosing (i.e., the tolerant state) than at the start of the study. This suggests that tolerance is unlikely to be caused by reduced bioavailability or accelerated elimination of ISDN. It is possible that tolerance is related to accumulation of ISDN metabolites. The attenuation of the circulatory response to ISDN may be related to the altered antianginal efficacy commonly seen during sustained therapy with ISDN.

This article has been cited by other articles:

				J. D. Parker and J. O. Parker Nitrate Therapy for Stable Angina Pectoris N. Engl. J. Med., February 19, 1998; 338(8): 520 - 531. [Full Text] [PDF]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 866 - 875. [Abstract] [Full Text]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker Effects of Diuretic Therapy on the Development of Tolerance to Nitroglycerin and Exercise Capacity in Patients With Chronic Stable Angina Circulation, February 15, 1996; 93(4): 691 - 696. [Abstract] [Full Text]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker Intermittent Transdermal Nitroglycerin Therapy : Decreased Anginal Threshold During the Nitrate-Free Interval Circulation, February 15, 1995; 91(4): 973 - 978. [Abstract] [Full Text]

				U. THADANI, S. F. HAMILTON, E. OLSON, J. ANDERSON, W. VOYLES, R. PRASAD, and S. M. TEAGUE Transdermal Nitroglycerin Patches in Angina Pectoris: Dose Titration, Duration of Effect, and Rapid Tolerance Ann Intern Med, October 1, 1986; 105(4): 485 - 492. [Abstract] [PDF]

				R. A. JORDAN, L. SETH, P. CASEBOLT, M. J. HAYES, M. M. WILEN, and J. FRANCIOSA Rapidly Developing Tolerance to Transdermal Nitroglycerin in Congestive Heart Failure Ann Intern Med, March 1, 1986; 104(3): 295 - 298. [Abstract] [PDF]

				J. ABRAMS Transdermal Nitroglycerin and Nitrate Tolerance Ann Intern Med, March 1, 1986; 104(3): 424 - 426. [Abstract] [PDF]

				M. Szycher Recent Advances in Transdermal Delivery Systems J Biomater Appl, January 1, 1986; 1(2): 207 - 238. [PDF]

				J. O. PARKER Efficacy of Nitroglycerin Patches: Fact or Fancy? Ann Intern Med, April 1, 1985; 102(4): 548 - 550. [Abstract] [PDF]